ID   U-2 OS R2
AC   CVCL_T430
SY   U-2OSR2
DR   Wikidata; Q54973539
RX   PubMed=17096323;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_T429 ! U-2 OS R1
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 12
//
RX   PubMed=17096323; DOI=10.1002/ijc.22327;
RA   Lourda M., Trougakos I.P., Gonos E.S.;
RT   "Development of resistance to chemotherapeutic drugs in human
RT   osteosarcoma cell lines largely depends on up-regulation of
RT   clusterin/apolipoprotein J.";
RL   Int. J. Cancer 120:611-622(2007).
//